Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)

US Patent 11118177 · Granted Sep 14, 2021

Estimated economic value: $24,558,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compositions and methods for treating and preventing macular degeneration2025
Compositions and methods for treating and preventing macular degeneration2025
Materials and methods for treatment of autosomal dominant retinitis pigmentosa2025
Materials and methods for treatment of autosomal dominant retinitis pigmentosa2025
AAV vectors for retinal and CNS gene therapy2025
Materials and methods for treatment of usher syndrome type 2A2025
Materials and methods for treatment of usher syndrome type 2A2025
Materials and methods for controlling gene editing2024
Materials and methods for treatment of usher syndrome type 2A and/or non-syndrom2024
Materials and methods for treatment of usher syndrome type 2A and/or non-syndrom2024
Materials and methods for treatment of usher syndrome type 2A and/or non-syndrom2024
Gene editing of deep intronic mutations2024